Akebia Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing and commercializing novel therapeutics for people with kidney disease. The company manufactures and markets a portfolio of primarily oral therapies including Auryxia (ferric citrate), indicated for control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and for treatment of iron deficiency anemia in non-dialysis-dependent CKD patients; and Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in Japan and launched in the U.S. for treating anemia associated with chronic kidney disease. Akebia’s operations mainly serve the United States and international markets, targeting patients with kidney disease and related complications. Founded in 2007 and headquartered in Cambridge, Massachusetts, the company also advances a pipeline of HIF-PH inhibitors and other kidney disease therapeutics in preclinical and clinical development. Recent significant changes include the U.S. commercial launch of Vafseo with broad contracts covering nearly 100% of U.S. dialysis patients through agreements with major dialysis organizations, positioning the drug as a potential new standard of care for anemia in CKD. The Centers for Medicare & Medicaid Services granted Transitional Drug Add-On Payment Adjustment (TDAPA) reimbursement for Vafseo, supporting market uptake. In 2025, Akebia expanded its rare kidney disease pipeline by acquiring global rights to ADX-097 (renamed AKB-097) from Q32 Bio, marking a strategic expansion beyond anemia therapies. Additionally, the company extended its supply agreement with STA Pharmaceutical through 2032 and completed executive management changes, including the appointment of a new Chief Financial Officer. Akebia continues to focus on label expansion for Vafseo into the non-dialysis CKD population, representing a significant market growth opportunity.
Company News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology